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Abstract
Objective
Investigate a combination of two clinically tested drugs, the NR2B antagonist Radiprodil and
the A2A antagonist Tozadenant in the MPTP-treated marmoset model of Parkinson’s Dis-
ease (PD).
Background
In PD, there remains a need for the development of non-dopaminergic drugs to effectively
treat the motor symptoms without the induction of L-Dopa-induced motor complications.
Methods
Clinically relevant doses of Radiprodil and Tozadenant were given both alone and in combi-
nation without the addition of L-Dopa, and the antiparkinsonian efficacy of the treatments
was assessed in a primate model of PD.
Results
When compared to the drugs tested alone, the drug combination led to a significant increase
of motor activity and an improvement of motor disability in MPTP-treated marmosets. In
addition, the motor restoration brought about by the combination was almost completely
devoid of dyskinesia. Interestingly, treated primates were not overstimulated, but were able
to move normally when motivated by the exploration of novel objects.
Conclusion
We have demonstrated in a primate model that, the “Radiprodil/Tozadenant” combination
significantly improves motor activity, extending previous results obtained in unilaterally
lesioned 6-OHDA-rats. The strength of the preclinical data accumulated so far suggests that
the use of such an A2A and NR2B antagonist combination could bring significant motor
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improvement to PD patients, without inducing the motor complications induced by L-Dopa
therapy. Although encouraging, these preclinical data need to be confirmed in the clinic.
Introduction
L-Dopa given together with a peripheral dopa-decarboxylase inhibitor still remains the gold
standard treatment for the motor symptoms of Parkinson’s disease (PD). However, long term
treatment with this combination invariably leads to debilitating side effects related to motor
complications (i.e. on-off motor fluctuations and dyskinesia) [1]. Long term experience with
L-Dopa demonstrates that the majority of treated patients experience dyskinesia, a percentage
that can rise to 80 to 90% after 10 years of treatment [2]. Consequently, the indentification of
efficacious non-dopaminergic pharmacotherapies which avoid these severe and predictable
motor complications remains a significant unmet need in the treatment of PD patients. For
this purpose, one could envisage the use of drugs which don’t directly stimulate the up-regu-
lated dopaminergic receptors in the lesioned striatum.
Over the last fifteen years, the adenosine A2 (A2A) receptor has emerged as an attractive tar-
get for PD treatment, given its functional interaction with dopamine receptors in the basal
ganglia [3,4]. In preclinical studies, A2A receptor antagonists, administered without L-Dopa,
have shown potential antiparkinsonian activity in rodent [5–7] and primate [8,9] models of
PD. Similarly, NR2B, a specific subunit of the N-methyl-D-Aspartate (NMDA) receptor, has
also been identified as an important player in PD symptomatology [10,11]. NR2B antagonists,
have been shown to have antiparkinsonian efficacy against motor symptoms in both rats [12]
and primates when used in the absence of L-Dopa [13]. As there is evidence suggesting that
the NMDA and A2A receptors interact, at least within the striatum [14], the therapeutic poten-
tial of the combined administration of A2A and NR2B antagonists was assessed in the unilateral
6-OHDA-lesioned rat PD model [15]. These rat data demonstrated that, when given in the
absence of L-Dopa, an NR2B and an A2A antagonist combination treatment was not only able
to substantially restore the quantity of movement but could also significantly improve the
quality of the movement when compared to L-Dopa. Furthermore, unlike L-Dopa, the combi-
nation treatment did not induce any involuntary movements in rats [16].
Unfortunately, some antiparkinsonian effects observed in preclinical models were not
reproduced in the clinic. For example, A2A antagonists failed to demonstrate significant effects
when given as monotherapy to patients [17] and while NR2B antagonists were shown to be
active against L-Dopa-induced dyskinesia (LIDs) [18], the only compound reportedly tested in
patients in the absence of L-Dopa (MK-0657) failed to show significant antiparkinsonian effi-
cacy [19]. These clinical outcomes may suggest that monotherapy with either an A2A or an
NR2B antagonist would not be sufficient to restore motor activity on their own.
In order to evaluate the effect of the A2A/NR2B combination in a model which more closely
resembles the clinical situation, the current study evaluated the antiparkinsonian effects of the
combined administration of Tozadenant and Radiprodil, given in the absence of L-Dopa, in
the 1-methyl-4-phenyl-1, 2, 3, 6,-tetrahydropyridine (MPTP)-treated marmoset model of PD.
Tozadenant is a selective A2A receptor antagonist which recently entered a Phase 3 trial [20]. It
has previously been shown to provide statistically significant clinical benefit on “on-time” and
to improve the UPDRS part III score in PD patients [21]. In contrast, Radiprodil is a NR2B-
selective NMDA receptor antagonist, initially developed for the treatment of neuropathic pain.
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However, its clinical development for pain was stopped in phase 2 due to a lack of efficacy
[22].
We hypothesized that the combination of the two above mentioned Phase 2/3 compounds,
tested in a primate model, would be more efficacious against the parkinsonian symptoms than
the compounds alone while being devoid of LID.
Materials and methods
Drugs
The vehicle was composed of 0.1% (w/v) Tween 80 (Sigma-Aldrich, UK), 0.1% (w/v) silicone
antifoam 1510 US (Dow Corning, US), 20% (w/v) Kleptose HPB (Roquette, Belgium), 1.0%
(w/v) methylcellulose (Sigma-Aldrich, UK) in water. Tozadenant (Biotie, US) was adminis-
tered as a suspension at a dose volume of 2 mL/kg by oral gavage. Radiprodil (UCB, Belgium)
was administered as a solution at a dose volume of 2 mL/kg by oral gavage. Dosing suspensions
were prepared approximately 18 hrs in advance and homogenised by using a polytron and
magnetic stirrer. L-DOPA methyl ester hydrochloride (4.0 mg/kg, Sigma-UK lot number
SLBD2579V, dose calculated as free base) was dissolved in a 10% sucrose solution containing
benserazide HCl (5mg/ml, see above) and administered in a volume of 2mL/kg by oral gavage
and prepared on the day of the experiment. Benserazide HCl (10 mg/kg, 5mg/mL, Sigma-UK
lot no. BCBB8323) was dissolved in a 10% (w/v) sucrose (lot no. SZB90120 Sigma-Aldrich,
UK) solution, freshly prepared on the day of the experiment.
Animals
All experiments were performed according to the Animals Scientific Procedures Act 1986 with
the guidelines of the European Community Council directive 2010/63/EU under Project
Licence No 70/7146 and, were approved for this specific study by the Animal Welfare & Ethi-
cal Review Board of King’s College London. Primates were housed at King’s College London,
Guy’s campus (UK) with a cage size of 163 cm in height, 140 cm of width and 90 cm in depth.
The cages could be subdivided into four equal sections. Half cages (Height 81 cm) were used
for severely disabled animals immediately after MPTP treatment. Following recovery from
MPTP the majority of animals were housed in full height cages. Several methods were used to
minimize any suffering for the primates (S1 File). At the end of the experimental period all ani-
mals were returned to the colony, and rested for at least two weeks prior to veterinary approval
for continued use in further studies.
Adult common marmosets (Callithrix jacchus; n = 12; body weight 350-500g, Harlan UK),
previously treated with MPTP (2.0mg/kg, sc) for five consecutive days and exhibiting stable
motor deficits at the start of experimentation were used [23]. Animals had been previously
primed to express mild to severe dyskinesia by chronic L-DOPA treatment and were not naïve
to test drugs [24]. Animals were housed according to UK Home Office Guidelines in male
(vasectomised) & female pairs where this was appropriate. The holding rooms were set for a 12
hours light/dark cycle (light on at 6:30 am, light off at 6:30 pm with periods of increasing/
decreasing light intensity to represent dawn and dusk) with a temperature range of 25 ± 1˚C
and 50% relative humidity. All animals had ad libitum access to food pellets (Marzuri primate
diet, Special Dietary Services) and water. They also received mashed Marzuri pellets and forage
mix in the morning and mixed fresh fruits in the afternoon. On the days of behavioural assess-
ment animals had free access to water but received food only at the end of the test period.
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Behavioural assessment
On the day of behavioural testing, animals were removed from their home cages between
07.15–07.30h and placed individually into the behavioural test cages and allowed to acclimatise
for 1 hour for the assessment of basal activity. Following the initial drug administration beha-
vioural assessments were then performed for 10 hours. To ensure maintenance of therapeutic
plasma levels throughout the whole observation period, a second dosing was given 5 hours
after the initial treatment, at which time a novel object (table tennis ball/ cotton reel) was
placed into the test cage. Experiments were performed twice weekly with an intervening period
of at least 2 days (wash out period). All the drug-treatment conditions were represented at
every testing session. Locomotor activity, Motor disability and Dyskinesia were evaluated as
described in the Supporting Information section (S1 File, “Behavioral analysis for the MPTP-
treated marmosets”) and raw data are available in S2–S4 Files.
Experimental design
Before initiating the Radiprodil & Tozadenant combination experiment, 14 primates were
challenged with a dose of 8 mg/kg (po) of L-Dopa and behaviour was recorded for 5 hours.
This “Pre-L-Dopa-test” was used to select the 12 subjects required for the study. Their
response to the L-Dopa challenge was subsequently used as a comparator to the ensuing
response to the different drug treatments and combinations. The effects of the drugs alone or
in combination were assessed after acute oral gavage.
This experiment investigated the effects on motor deficits of Radiprodil plus Tozadenant
twice daily at an interval of 5 hrs according to a modified Latin square design in n = 12 MPTP-
treated marmosets (S1 Table). At the time of the second drugs administration a novel object
(cotton reel, table tennis ball) was placed into the cage. The four different treatments were (1)
Tozadenant (150 mg/kg) plus Radiprodil (2.0 mg/kg), (2) Tozadenant (150 mg/kg) plus vehi-
cle, (3) Radiprodil (2.0 mg/kg) plus vehicle, (4) vehicle.
Statistical analysis
The data were recorded over a period of 10 hours subdivided within two periods: pre-object
placement (period 1) and post-object placement (period 2). The total scores of the activity
counts of the first and second period were used as dependent variables for locomotor activity.
For the disability score, to allow parametric statistical analyses, the sum of the number of
observation sequences with a score below 8 (on-time activity) was taken as the dependent vari-
able for period 1 and period 2. For locomotor activity and disability score, the effect of Radi-
prodil and Tozadenant were assessed with three-way mixed design ANOVA, incorporating
the effect of Tozadenant (2 levels, vehicle and the dose of 150 mg/kg) and the effect of Radipro-
dil (2 levels, vehicle and the dose of 2 mg/kg) as between-group factors, and the Period (2 lev-
els, pre-object and post-object) as within-subjects factors. The reliability of the between-mean
differences for each relevant comparison was assessed via planned orthogonal contrasts using
an F statistic. As necessary, logarithmic transformations to normalise raw data prior to the sta-
tistical analysis, were performed to more precisely meet the assumption of homogeneity of var-
iances (Levene’s test). For the sake of clarity, however, means of the raw values are presented
in the figures. Statistical significance was set at p<0.05. The dyskinesia total score was analysed
with non-parametric statistics. Statistical analyses were performed using the Prism (GraphPad
software) and Statistica (StatSoft Inc., OK, USA) software.
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Pharmacokinetics
At the indicated times, blood samples were collected from the femoral vein. These samples
were collected in EDTA tubes, centrifuged to obtain plasma and stored at -70˚C until mass
spectrometry analysis (for detailed description of the methods see S1 File).
Results
Dose regimen selection for MPTP-treated marmosets
The doses used for the A2A and NR2B antagonists combination were selected to provide the
same plasma exposure values as those found to be active in the previously reported 6-OHDA
rat study [15]. In the rodent PD model, the orally active dosing regimen of 3 mg/kg of Radi-
prodil combined with 30 mg/kg of Tozadenant was associated with plasma levels of 522 ng/mL
Radiprodil and 6054 ng/mL Tozadenant (measured at 60 min). Similar exposure was achieved
in the present MPTP-treated marmoset model after oral dosing of 2 mg/kg Radiprodil and 150
mg/kg Tozadenant (S1 Fig). As observed in rat, Radiprodil and Tozadenant do not show a
pharmacokinetic interaction when co-administered (S2 Fig). The plasma levels measured in
the marmoset were sustained (t1/2 3h) and in the same range as those achieved in the Phase
2 trials with 120 mg BID Tozadenant [25] and 45 mg TID Radiprodil (unpublished; data on
UCB files).
The “Radiprodil and Tozadenant” combination improves the
parkinsonian symptoms in MPTP-treated marmosets
Locomotor activity. When treated with the Radiprodil/Tozadenant combination (2 mg/
kg Radiprodil and 150 mg/kg Tozadenant), MPTP-treated marmosets (n = 12), showed a sig-
nificant increase in motor activity (Fig 1 left graph) in comparison to the effect of the drugs
alone. In comparison with L-Dopa (Fig 1, right graph), the Radiprodil and Tozadenant combi-
nation showed a very different profile of efficacy with a slower initiation of the activity. How-
ever, this effect lasted longer and reached a similar magnitude as that observed with L-Dopa.
Both Radiprodil and Tozadenant significantly contributed to the increased locomotor activ-
ity in MPTP-treated marmosets (significant effect of Tozadenant [F(1,44) = 5.47, p<0.05];
significant effect of Radiprodil [F(1,44) = 15.82, p<0.001]; no Tozadenant x Radiprodil inter-
action). The addition of a novel object to the testing environment and the second drug chal-
lenge also contributed significantly to the increase of the activity [Period: F(1,44) = 59.49,
p<0.001]. Planned contrasts (Fig 2) showed that for the first period, animals treated with the
Radiprodil/Tozadenant combination had a significantly higher level of locomotor activity than
the vehicle and the Tozadenant group (p<0.01). By contrast, for the second period, the group
treated with the Radiprodil/Tozadenant combination had significantly higher levels of loco-
motor activity than the groups treated with Vehicle (p<0.01), Tozadenant (p<0.01) and Radi-
prodil (p<0.05). Also, the Radiprodil/Tozadenant-treated group showed a significantly higher
level of locomotor activity during the second period, with the object present in the test cage,
in comparison to the activity measured during the first period in the absence of the object
(p<0.01).
Motor disability. When administered together to MPTP-treated primates, both Radipro-
dil and Tozadenant significantly contributed to the improvement of the disability score (Fig 3,
left graph). As observed previously with locomotor activity, the Radiprodil & Tozadenant com-
bination showed a very different profile to that observed with L-Dopa (Fig 3, right graph). A
delay of the improvement of motor disability was observed but, the efficacy of the drug combi-
nation lasted longer than that observed with L-Dopa. However, the drug combination did not
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Fig 1. Comparison of the effects of the “Radiprodil and Tozadenant” combination with the effects of L-Dopa on the level of locomotor activity
in MPTP-treated marmosets. Left graph: Lomotor activity (mean value ± SEM) measured over 10 hours following Radiprodil (2 mg/kg) and Tozadenant
(150 mg/kg) treatment given alone or in combination in MPTP-treated marmosets (n = 12). Five hours after the first drug administration, a second
administration was given and, at the same time, novel objects were introduced in the testing cage. * versus Radiprodil group (one-way ANOVA, p<0.01,
followed by planned contrasts). Right graph: Locomotor activity measured over 5 hours follwing L-Dopa (8 mg/kg). p<0.001 L-Dopa vs Vehicle (Student
test on total score).
https://doi.org/10.1371/journal.pone.0182887.g001
Fig 2. Statistical analysis of the “Radiprodil and Tozadenant” combination in MPTP-treated
marmosets for the level of locomotor activity. Increased level of locomotor activity with Radiprodil (2 mg/
kg) and Tozadenant (150 mg/kg) treatment when given alone or in combination in MPTP-treated marmosets
(n = 12/group). Period 1 corresponds to the effect observed when the animals were in their usual testing
environment. Period 2 corresponds to the period of time wherein the primates received the second drug
administration and when the novel objects were put in the testing cage (Two-way mixed ANOVA followed by
planned contrasts with *, p<0.05 and **, p<0.01).
https://doi.org/10.1371/journal.pone.0182887.g002
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succeed to reach a comparable amplitude of the motor improvement to that observed with
L-Dopa.
As observed in Fig 4, a significant effect of Radiprodil [F(1,44) = 13.42, p<0.001] and of
Tozadenant [F(1,44) = 10.87, p<0.01] was observed but no “Radiprodil x Tozadenant”
(p = 0.29) interaction. The introduction of the novel object also contributed to the significant
improvement of motor disability scores [Period: F(1,44) = 5.88, p<0.05]. Planned contrasts for
period 1 and 2 showed that, during these two periods, the Radiprodil/Tozadenant group dis-
played longer time with improved motor disability score than the vehicle, Tozadenant and
Radiprodil groups (p<0.05 and p<0.01). Also, the Radiprodil/Tozadenant group showed
improved motor activity at the second period in comparison to the first one (p<0.01). Conse-
quently, these data demonstrate that the on-time duration is longer under the combination
rather than under the drugs alone and the observation is reinforced when novel objects are
introduced in the test cage.
Dyskinesia. When administered to MPTP-treated primates, both Radiprodil and Tozade-
nant administered alone or together did not induce a significant level of dyskinesia over the 10
hours of behavioural observation (Fig 5, left graph). Only three subjects demonstrated very
minor dyskinesia. By contrast, the level of dyskinesia observed with L-Dopa was, as expected,
much higher than the vehicle treatment (p<0.01) (Fig 5, right graph).
Discussion
In the current study, we used a bilateral primate model of PD to demonstrate that the com-
bined administration of A2A and NR2B receptor antagonists significantly increases the level
of motor activity and substantially improves the parkinsonian disability score. Drugs were
administered orally in combination at clinically relevant doses to MPTP-treated marmosets
without L-Dopa. This work confirms and extends previous studies in unilaterally-lesioned rats
Fig 3. Comparison of the effects of the “Radiprodil and Tozadenant” combination with the effects of L-Dopa on the disability score in MPTP-
treated marmosets. Left graph: Motor disability score (median value) recorded over 10 hours following Radiprodil (2 mg/kg) and Tozadenant (150 mg/kg)
treatment given alone or in combination in MPTP-treated marmosets (n = 12). Five hours after the first drug administration, a second administration was
given and, at the same time, novel objects were introduced in the testing cage. The score of 8 relates to the threshold below which the behaviours
recorded corresponded to the definition of “on-time” activity (One-way ANOVA, p<0.01, Kruskal-Wallis). Right graph: Disability scored measured over 5
hours following L-Dopa (8 mg/kg). p<0.001 L-Dopa vs Vehicle (Mann-Whitney test on total score).
https://doi.org/10.1371/journal.pone.0182887.g003
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where the NR2B/A2A antagonist combination proved to be significantly more effective than
the individual drugs alone [15,16]. The most striking observation in the present primate study
was the long-lasting restoration of movement which was not accompanied by any dyskinesia
even though the primates had been L-Dopa primed prior to drug administration.
Radiprodil by itself had some motor effects in marmosets since it was associated with a
small increase in locomotor activity, although it had no effect on motor disability scores. This
observation is consistent with previous reports showing the anti-parkinsonian potential of
NR2B antagonist drugs in the same animal model [12,13]. Tozadenant, by contrast, did not
show any significant antiparkinsonian activity when given alone. This differs from previous
studies with two other A2A antagonists, Preladenant and Istradefylline, which were reported to
elicit mild antiparkinsonian effects when given to primates as monotherapy [8,9,26,27].
In order to be able to demonstrate the long lasting beneficial effect of the combination on
primate behaviour, the protocol of the present study was adapted to overcome the fact that the
animals were habituated to their environment. The two drugs were devoid of any direct dopa-
minergic stimulation and thus were not expected to produce behavioural hyperstimulation. In
previous experiments, performed with unilateral 6-ODHA-lesioned rats, the NR2B/A2A com-
bination significantly increased the level of locomotor activity. Instead of the typical contralat-
eral rotations observed with dopaminergic drugs, the combination produced an increased
exploratory activity accompanied by a restoration of fluid, coordinated and symmetrical quad-
ripedal movements which looked similar to that observed with mildly stimulated non-lesioned
rats [15,16,28]. In addition, we also noticed that after chronic treatment with the combination,
the unilateral-lesioned rats did not develop any abnormal movements but rather developed an
Fig 4. Statistical analysis of the “Radiprodil and Tozandenant” combination in MPTP-treated
marmosets for the disability score. Sum of the number of observation sequences (means ± SEM) wherein the
primates’ behaviour was assessed as ‘on-time’ activity (motor disability scoring<8). The behaviour was scored
over 10 hours after Radiprodil (2 mg/kg) and Tozadenant (150 mg/kg) treatment given alone or in combination in
MPTP-treated marmosets (n = 12/group). Period 1 corresponds to the effect observed when the animals are in
the usual testing cage. Period 2 indicates the effect associated with the second drug administration and the
introduction of a novel object in the testing environment (Two-way mixed ANOVA followed by planned contrasts
with *, p<0.05 and **, p<0.01).
https://doi.org/10.1371/journal.pone.0182887.g004
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habituation to the testing environment resulting in decreased exploratory behaviour, making
behavioural scoring difficult. However, the increase in motor activity became strongly evident
when the rats were placed into a novel testing context, wherein normal exploratory activity
returned, indicating that the pseudo tolerance effect resulted from the elementary learning
process of Habituation rather than from a pharmacological effect (unpublished data). Habitua-
tion is an adaptive mechanism which requires maturation and integrity of the central nervous
system [29,30]. Consequently, it can be hypothesized that the combination treatment did not
disrupt the normal cognitive functioning of the lesioned rats.
As MPTP-treated marmosets were highly habituated to their testing environment, a novel
object was introduced to the testing cage to encourage them to move while exploring and thus
facilitate behavioural scoring. The results demonstrated that the MPTP-treated marmosets
were not hyperstimulated as observed with dopaminergic drugs. They reacted to the presence
of the novel object in the cage and explored it. They all showed a significant increase of loco-
motor activity. However, only the primates treated with the combo demonstrated a significant
improvement of motor disability and this effect was not accompanied by abnormal move-
ments. These results confirm, in primates, what was previously observed with unilateral
6-OHDA-lesioned rats, namely that the combination treatment is able to restore good quality
motor activity in the absence of motor complications and in the absence of stereotyped behav-
iour that would prevent normal exploration.
In preclinical models, rather than habituation, current dopaminergic therapies typically give
rise to behavioural sensitization which translates to a progressive enhancement of motor activ-
ity by repeated administration of stimulant drugs when given in association with a specific test-
ing context [31]. A phenomenon not only observed with psychostimulants (e.g. cocaine and
amphetamine), but also attributed to treatment with L-Dopa in 6-OHDA-lesioned rodents [32]
and MPTP-treated marmosets [33]. This L-Dopa-induced phenomenon is likely to be related
to the development of LIDs. Even if the experiment did not address the chronic effect of the
combination, the MPTP-treated marmosets which had been L-Dopa-primed, did not show any
signs of abnormal movements after treatment with the combination. This observation strongly
suggests that the NR2B/A2A antagonist combination does not possess a pro-dyskinetic potential
in primates, and our extensive previous studies have confirmed that this is also the case in
Fig 5. Comparison of the effects of the “Radiprodil and Tozadenant” combination with L-Dopa on the level
of dyskinesia in MPTP-treated marmosets. Data are individual scores. Left graph: dyskinesia score in MPTP-
treated marmosets having received Radiprodil (2 mg/kg) and Tozadenant (150 mg/kg) treatment alone or in
combination over the 10-hour of behavioural recording. Right graph: dyskinesia scores recorded over 5 hours after
L-Dopa treatment (8 mg/kg; **, p<0.05, Mann-Withney test).
https://doi.org/10.1371/journal.pone.0182887.g005
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rodents [28]. In the absence of any experimental evidence supporting a biological rationale, the
interpretation of the behavioural observations remain hypothetical. One might speculate that
the improvement of motor disability observed under the A2A/NR2B combination is due to a
restoration of the balance of the dysregulated circuits of the basal ganglia. First, the behavioural
improvement could result from the attenuation of the enhanced A2A receptor tone which is a
characteristic of the 6-OHDA-lesioned rats [34]. This A2A antagonist effect on behaviour could
be further enhanced by the inhibition of the NR2B receptor since these two receptors share a
common intracellular signaling pathway [14]. Consequently, the efficacy of Tozadenant would
be enhanced by the co-treatment with Radiprodil since mutual inhibition would result in a sig-
nificant benefit. Also, it has been shown that, in the hippocampus, the A2A receptor elicits the
phosphorylation of the NR2B subunit (Tyr1472) that is required for the mGLUR5-mediated
potentiation of the NMDA response [35]. If a comparable phenomenon also occurs in the stria-
tum, one might expect that blocking the A2A activity could prevent the Fyn-mediated tyrosine
NR2B phosphorylation process involved in the development of L-Dopa sensitization [36] and
of dyskinesia [37,38] when the direct D1 striatal pathway is stimulated.
In summary, this study reproduces, in a bilateral primate model of Parkinson’s disease, the
motor improvements observed with the Radiprodil/Tozadenant combination in unilaterally
6-OHDA-lesioned rats. The strength of the accumulated preclinical data using these two mod-
els suggests that the combination of two clinical candidate drugs, Radiprodil and Tozadenant,
could bring motor improvements while being unlikely to cause mechanism-based side effects.
If these results can be further validated in a clinical study, it would make a strong case for con-
sidering the combined administration of an NR2B and A2A antagonist for the symptomatic
treatment of parkinsonian patients.
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